BNTX vs. MRNA

Last updated Jun 3, 2026

BNTX (BioNTech SE) and MRNA (Moderna, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, BNTX returned -15.79%/yr vs -25.22%/yr for MRNA. A 0.56 correlation means they provide meaningful diversification when combined.

Performance

BNTX vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioNTech SE (BNTX) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BNTX achieves a -6.37% return, which is significantly lower than MRNA's 54.76% return.

BNTX

• 1D: -2.79%
• 1M: -8.61%
• YTD: -6.37%
• 6M: -7.25%
• 1Y: -21.18%
• 3Y*: -6.23%
• 5Y*: -15.79%
• 10Y*: —

MRNA

• 1D: -0.91%
• 1M: 0.60%
• YTD: 54.76%
• 6M: 89.69%
• 1Y: 68.72%
• 3Y*: -29.55%
• 5Y*: -25.22%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BNTX vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
BNTX BioNTech SE	-6.37%	-16.45%	7.97%	-29.74%	-40.40%	216.24%	140.61%	137.92%
MRNA Moderna, Inc.	54.76%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	38.14%

Correlation

The correlation between BNTX and MRNA is 0.57, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.57
Correlation (3Y) Calculated over the trailing 3-year period	0.59
Correlation (5Y) Calculated over the trailing 5-year period	0.68
Correlation (All Time) Calculated using the full available price history since Oct 11, 2019	0.56

The correlation between BNTX and MRNA shifts across timeframes, from 0.56 (all time) to 0.68 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap BNTX : $22.54B MRNA : $18.03B
EPS BNTX : -$5.14 MRNA : -$8.16
PS Ratio BNTX : 7.79 MRNA : 8.03
PB Ratio BNTX : 1.20 MRNA : 2.43
Total Revenue (TTM) BNTX : $2.80B MRNA : $2.23B
Gross Profit (TTM) BNTX : $2.05B MRNA : -$309.00M
EBITDA (TTM) BNTX : -$815.04M MRNA : -$3.02B

Return for Risk

BNTX vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BNTX

BNTX Risk / Return Rank: 24
BNTX Sharpe Ratio Rank: 18
BNTX Sortino Ratio Rank: 19
BNTX Omega Ratio Rank: 18
BNTX Calmar Ratio Rank: 32
BNTX Martin Ratio Rank: 31

MRNA

MRNA Risk / Return Rank: 72
MRNA Sharpe Ratio Rank: 73
MRNA Sortino Ratio Rank: 73
MRNA Omega Ratio Rank: 68
MRNA Calmar Ratio Rank: 74
MRNA Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BNTX vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioNTech SE (BNTX) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BNTX	MRNA	Difference
Sharpe ratio Return per unit of total volatility	-0.52	1.09	-1.60
Sortino ratio Return per unit of downside risk	-0.49	1.93	-2.42
Omega ratio Gain probability vs. loss probability	0.93	1.22	-0.29
Calmar ratio Return relative to maximum drawdown	-0.23	2.02	-2.26
Martin ratio Return relative to average drawdown	-0.49	4.02	-4.51
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BNTX vs. MRNA - Sharpe Ratio Comparison

The current BNTX Sharpe Ratio is -0.52, which is lower than the MRNA Sharpe Ratio of 1.09. The chart below compares the historical Sharpe Ratios of BNTX and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BNTX	MRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.52	1.09	-1.60
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	-0.38	+0.10
Sharpe Ratio (All Time) Calculated using the full available price history	0.42	0.18	+0.25

Drawdowns

BNTX vs. MRNA - Drawdown Comparison

The maximum BNTX drawdown since its inception was -82.08%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for BNTX and MRNA.

Drawdown Indicators

	BNTX	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-82.08%	-95.38%	+13.30%
Max Drawdown (1Y) Largest decline over 1 year	-29.71%	-35.51%	+5.80%
Max Drawdown (3Y) Largest decline over 3 years	-37.35%	-86.58%	+49.23%
Max Drawdown (5Y) Largest decline over 5 years	-82.08%	-95.38%	+13.30%
Current Drawdown Current decline from peak	-79.61%	-90.58%	+10.97%
Average Drawdown Average peak-to-trough decline	-56.11%	-56.62%	+0.51%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.20%	17.87%	-3.67%

Volatility

BNTX vs. MRNA - Volatility Comparison

The current volatility for BioNTech SE (BNTX) is 9.26%, while Moderna, Inc. (MRNA) has a volatility of 17.07%. This indicates that BNTX experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BNTX	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.26%	17.07%	-7.81%
Volatility (6M) Calculated over the trailing 6-month period	34.24%	48.11%	-13.87%
Volatility (1Y) Calculated over the trailing 1-year period	44.88%	63.55%	-18.67%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	55.62%	66.32%	-10.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	76.34%	71.89%	+4.45%

Dividends

BNTX vs. MRNA - Dividend Comparison

Neither BNTX nor MRNA has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022
BNTX BioNTech SE	0.00%	0.00%	0.00%	0.00%	2.43%
MRNA Moderna, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both BNTX and MRNA in my portfolio?

BNTX and MRNA have a correlation of 0.57, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BNTX or MRNA?

MRNA has higher volatility (17.07%) compared to BNTX (9.26%). In terms of maximum drawdown, BNTX dropped -82.08% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (1.09 vs -0.52), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.